Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
- The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.
- The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.
- The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.
- To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.